Abbott India Limited Stock Price Today (NSE: ABBOTINDIA)
Fundamental Score
Abbott India Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Abbott India Limited share price today is ₹26125.00, up +0.00% on NSE/BSE as of 16 September 2026. Abbott India Limited (ABBOTINDIA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹58.69K (Cr). The 52-week high for ABBOTINDIA share price is ₹31355.00 and the 52-week low is ₹25135.00. At a P/E ratio of 37.82x, ABBOTINDIA is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 34.46% and a debt-to-equity ratio of 0.04.
Abbott India Limited Share Price Chart — NSE/BSE Historical Performance
Abbott India Limited share price chart: -7.19% return over the past month. 52-week high ₹31355.00, 52-week low ₹25135.00.
Abbott India Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹26195.00 | ₹26450.00 | ₹25500.00 | ₹26125.00 | 5.68K (Cr) | |
| ₹25690.00 | ₹26245.00 | ₹25550.00 | ₹26125.00 | 10.73K (Cr) | |
| ₹25260.00 | ₹25635.00 | ₹25135.00 | ₹25550.00 | 9.62K (Cr) | |
| ₹25245.00 | ₹25395.00 | ₹25205.00 | ₹25260.00 | 7.22K (Cr) | |
| ₹25555.00 | ₹25705.00 | ₹25190.00 | ₹25225.00 | 6.05K (Cr) | |
| ₹25860.00 | ₹26065.00 | ₹25440.00 | ₹25555.00 | 11.09K (Cr) | |
| ₹26150.00 | ₹26195.00 | ₹25810.00 | ₹25940.00 | 5.39K (Cr) | |
| ₹25945.00 | ₹26365.00 | ₹25810.00 | ₹26065.00 | 8.80K (Cr) | |
| ₹26175.00 | ₹26175.00 | ₹25905.00 | ₹25945.00 | 3.15K (Cr) | |
| ₹26185.00 | ₹26265.00 | ₹25810.00 | ₹26045.00 | 7.83K (Cr) |
Abbott India Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹25880.00 | ₹26450.00 | ₹25135.00 | ₹26125.00 | +0.95% | |
| ₹27950.00 | ₹28635.00 | ₹25800.00 | ₹25850.00 | -7.51% | |
| ₹25585.00 | ₹28940.00 | ₹25370.00 | ₹27800.00 | +8.66% | |
| ₹27095.00 | ₹27175.00 | ₹25200.00 | ₹25440.00 | -6.11% | |
| ₹25480.00 | ₹28280.00 | ₹25175.00 | ₹26855.00 | +5.40% | |
| ₹26415.00 | ₹26550.00 | ₹25150.00 | ₹25435.00 | -3.71% | |
| ₹26025.00 | ₹28490.00 | ₹25350.00 | ₹25915.00 | -0.42% | |
| ₹27470.00 | ₹27910.00 | ₹26075.00 | ₹26530.00 | -3.42% | |
| ₹28860.00 | ₹28990.00 | ₹26430.00 | ₹27565.00 | -4.49% | |
| ₹30200.00 | ₹30200.00 | ₹27430.00 | ₹29025.00 | -3.89% | |
| ₹29000.00 | ₹30655.00 | ₹28600.00 | ₹30075.00 | +3.71% | |
| ₹29500.00 | ₹30560.00 | ₹28900.00 | ₹28995.00 | -1.71% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Abbott India Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Abbott India Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ABBOTINDIA across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (34.46%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (44.89%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (24.90%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Excellent EPS Growth (17.57% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (17.57% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.04)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (84.20x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 3.39)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹5194.95 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (74.99%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
High Price-to-Book Ratio (13.11x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Limited Institutional Interest (FII+DII: 9.20%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Abbott India Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Abbott India Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Abbott India LimitedAbbott India Li...Selected✓ ABBOTINDIA • 500488 | 62.3/100 | ₹26125.00₹26125 | ₹58692.31₹58692.31 | 37.82Average 37.8 Average | 34.46%Excellent 34.46% Excellent | 44.89%Excellent 44.89% Excellent | 0.04Excellent 0.0 Excellent | 17.57%Excellent 17.57% Excellent | 9.96%Good 9.96% Good | 1.90% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Abbott India Limited PE Ratio History
Historical price-to-earnings ratio for ABBOTINDIA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹665.62 | ₹29025.00 | 43.6x |
| FY 2024 | ₹565.28 | ₹29741.00 | 52.6x |
| FY 2023 | ₹446.78 | ₹22851.25 | 51.1x |
| FY 2022 | ₹375.86 | ₹21367.20 | 56.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Abbott India Limited Dividend History
Annual cash dividends paid by ABBOTINDIA — dividend yield 1.90%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹871.22 Cr |
| FY 2024 | ₹690.60 Cr |
| FY 2023 | ₹584.36 Cr |
| FY 2022 | ₹584.36 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Abbott India Limited Quarterly Performance
Latest quarterly metrics for ABBOTINDIA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
6.54%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
7.60%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.96%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
17.57%
Compounded annual net profit growth over 5 years
Abbott India Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ABBOTINDIA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Abbott India Limited Financial Statements
Annual income statement, balance sheet and cash flow for Abbott India Limited (ABBOTINDIA) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Abbott India Limited
About ABBOTINDIA (Abbott India Limited)
Abbott India Ltd is a prominent player in the Indian pharmaceutical landscape, dedicated to delivering a diverse portfolio of healthcare solutions. With a legacy rooted in innovati...on and patient-centricity, the company focuses on addressing critical health needs across various therapeutic areas. Abbott India's commitment extends to providing high-quality medicines and solutions accessible to a broad spectrum of the Indian population. Through strategic collaborations and a robust research and development pipeline, the company continues to enhance its offerings, striving to improve the lives of individuals and contribute to a healthier nation. Its presence resonates with trust and reliability, solidifying its position as a leading pharmaceutical organization in India. The company's pharmaceutical products cater to a wide range of medical specialties, encompassing areas like gastroenterology, women's health, metabolic disorders, and central nervous system conditions. It offers solutions for conditions like insomnia, vitamin D deficiency, and pre-term labor, and chronic pain management. Abbott India also manufactures and sells vaccines to prevent infections and protect populations. This diverse portfolio reflects a comprehensive approach to healthcare, addressing both prevalent and emerging medical challenges in the country. By focusing on innovation and quality, Abbott India ensures that patients have access to effective and reliable treatments, improving overall health outcomes and well-being. Beyond its core therapeutic areas, Abbott India extends its pharmaceutical reach into segments like anti-infectives, cardio-diabetology, gastrointestinal and hepatology, hormones, neuropsychiatry, respiratory illnesses, and neuroscience. In addition, Abbott India offers a range of products targeting hepatic conditions, metabolic disorders, and gennext healthcare needs, solidifying its commitment to holistic well-being. Furthermore, the company provides consumer healthcare products designed to promote preventative care and healthy living. Through this diverse range of solutions, Abbott India demonstrates its dedication to addressing a wide spectrum of health requirements, reinforcing its role as a trusted partner in India's healthcare ecosystem.
Company Details
Key Leadership
ABBOTINDIA Share Price: Frequently Asked Questions
What is the current share price of Abbott India Limited?
Abbott India Limited (ABBOTINDIA) trades at ₹26125.00 on NSE and BSE. Market cap ₹58.69K (Cr). Educational data only.
What is the P/E ratio of Abbott India Limited?
Abbott India Limited has a P/E of 37.82x vs industry average 34.89x.
What is the Bull Run score for Abbott India Limited?
Abbott India Limited has a Bull Run score of 62.3/100 based on 25+ financial parameters.
Does Abbott India Limited pay dividends?
Abbott India Limited has a dividend yield of 1.90%. Past dividends don't guarantee future payments.
What is the ROE of Abbott India Limited?
Abbott India Limited has ROE of 34.46%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Abbott India Limited?
Abbott India Limited has debt-to-equity of 0.04.
Is Abbott India Limited a good investment?
Bull Run gives Abbott India Limited a score of 62.3/100. This is not investment advice — consult a SEBI-registered advisor.